Panax ginsenosides




















Main Active Compounds:


  1. Ginsenosides Rb1, Rg1



Systematic Review:

P. notoginseng plays a role in improving the local blood supply, stimulating circulation to end stasis, it possesses the effect of dilation of cerebral blood vessels, changes hemorheological characteristic,prevents thrombosis and promotes fibrinolysis (1). 


Clinical Trials:

"RG could be an attractive herbal dietary supplement for relieving menopausal symptoms and conferring favorable effects on markers of cardiovascular disease in postmenopausal women." (136).


"Three (3) months' treatment with Korean Red Ginseng did not improve arterial stiffness in subjects with hypertension." (137).


Peer Review:

Ginsenosides can inhibit ROS production, stimulate NO production, increase blood circulation, ameliorate vasomotor tone, and adjust lipid profi le. Additionally, many studies indicate that ginsenosides have a multitude of activities in both physiological and/or pathologic conditions concerning with CVD. 


Experimental Research:

Ginsenosides prevent free radicals from damaging cardiac muscle cells


2 main active ginsenosides: protopanaxdiol Rb1 and protopanaxatriol Rg1.


Rb1 and Rg1 protect heart muscle by regulation of cAMP/cGMP values. One of the factors that leads to remediation of cardiac arrhythmia.


Taking excess calcium will cause blood vessels to tense up and contract and increase blood pressure, and thus increase the chance of a heart attack. There are calcium channel blockers drugs one can take (CCBs) which relax blood vessels and decrease blood pressure (8). Rg1 selectively counters blood vessel constriction caused by calcium ions, it is a natural calcium channel blocker. 


Calcium Channel Blockers and Nitrates (for NO production) help prevent angina and high blood pressure. (138). 


Rb1 and Rg1 increased vessel dialation that is endothelial cell dependent by activating nitric oxide and also regulates L-arginine and the PI3K/Akt/eNOS pathway in the endothelium cells.





Peer Review References by 


Kim. J. H.  Cardiovascular Diseases and Panax ginseng: A Review on Molecular Mechanisms and Medical Applications. JGR Journal of Ginseng Research, Volume 36, No.1, 2012,  pp 16-26, (References 1-128). 






1. Kritharides L, Brown A, Brieger D, Ridell T, Zeitz C,Jeremy R, Tonkin A, Walsh W, White H. Overview anddeterminants of cardiovascular disease in indigenouspopulations. Heart Lung Circ 2010;19:337-343. 52. Pratt C. Alternative prevention and treatment of cardiovasculardisease, part 2. Prim Care 2010;37:339-366.53. Ulrich S, Hingorani AD, Martin J, Vallance P. Lifetimerisk of developing coronary heart disease. Lancet1999;353:925.54. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M,Cepaitis Z, Kuulasmaa K, Keil U. Estimation of contributionof changes in coronary care to improving survival,event rates, and coronary heart disease mortalityacross the WHO MONICA Project populations. Lancet2000;355:688-700.55. Toth PP. Making a case for quantitative assessment of cardiovascularrisk. J Clin Lipidol 2007;1:234-241.56. Libby P. What have we learned about the biology ofatherosclerosis? The role of infl ammation. Am J Cardiol2001;88(7B):3J-6J.57. Libby P. Act local, act global: infl ammation and the multiplicityof “vulnerable” coronary plaques. J Am Coll Cardiol2005;45:1600-1602.58. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N,Katz D, Kyriakopoulos A. The expression of the adhesionmolecules ICAM-1, VCAM-1, PECAM, and E-selectinin human atherosclerosis. J Pathol 1993;171:223-229.59. Tabas I. Consequences and therapeutic implications ofmacrophage apoptosis in atherosclerosis: the importanceof lesion stage and phagocytic efficiency. ArteriosclerThromb Vasc Biol 2005;25:2255-2264.10. Tabas I, Williams KJ, Boren J. Subendothelial lipoproteinretention as the initiating process in atherosclerosis:update and therapeutic implications. Circulation2007;116:1832-1844.11. Schechter CB. Longevity and cardiovascular disease: contextand overview. Arch Intern Med 2007;167:428-429.12. Boudina S, Laclau MN, Tariosse L, Daret D, GouverneurG, Bonoron-Adele S, Saks VA, Dos Santos P. Alterationof mitochondrial function in a model of chronic ischemiain vivo in rat heart. Am J Physiol Heart Circ Physiol 22J. Ginseng Res. Vol. 36, No. 1, 16-26 (2012)2002;282:H821-H831.13. Shibata S, Fujita M, Itokawa H, Tanaka O, Ishii T. Studieson the constituents of Japanese and Chinese crude drugs.XI. Panaxadiol, a sapogenin of ginseng roots. ChemPharm Bull (Tokyo) 1963;11:759-761.14. Shibata S, Tanaka O, Soma K, Ando T, Iida Y, NakamuraH. Studies on saponins and sapogenins of ginseng. Thestructure of panaxatriol. Tetrahedron Lett 1965;42:207-213.15. Gillis CN. Panax ginseng pharmacology: a nitric oxidelink? Biochem Pharmacol 1997;54:1-8.16. Buettner C, Yeh GY, Phillips RS, Mittleman MA,Kaptchuk TJ. Systematic review of the effects of ginsengon cardiovascular risk factors. Ann Pharmacother2006;40:83-95.17. Hofseth LJ, Wargovich MJ. Inflammation, cancer, andtargets of ginseng. J Nutr 2007;137(1 Suppl):183S-185S.18. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology:multiple constituents and multiple actions. Biochem Pharmacol1999;58:1685-1693.19. Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q, ChenCJ. Molecular mechanisms and clinical applications ofginseng root for cardiovascular disease. Med Sci Monit2004;10:RA187- RA192.20. Cheng Y, Shen LH, Zhang JT. Anti-amnestic and anti-agingeffects of ginsenoside Rg1 and Rb1 and its mechanismof action. Acta Pharmacol Sin 2005;26:143-149.21. Fuzzati N. Analysis methods of ginsenosides. J ChromatogrB Analyt Technol Biomed Life Sci 2004;812:119-133.22. Nah SY, Kim DH, Rhim H. Ginsenosides: are any ofthem candidates for drugs acting on the central nervoussystem? CNS Drug Rev 2007;13:381-404.23. Brekhman II, Dardymov IV. New substances of plantorigin which increase nonspecific resistance. Annu RevPharmacol 1969;9:419-30.24. Bittles AH, Fulder SJ, Grant EC, Nicholls MR. The effectof ginseng on lifespan and stress responses in mice. Gerontology1979;25:125-131.25. Zhou DH. Preventive geriatrics: an overview from traditionalChinese medicine. Am J Chin Med 1982;10:32-39.26. Brekhman II. Panax ginseng. Leningrad: Gosudaarst Isdatet Med Lit, 1957.27. Jiang QS, Huang XN, Dai ZK, Yang GZ, Zhou QX, ShiJS, Wu Q. Inhibitory effect of ginsenoside Rb1 on cardiachypertrophy induced by monocrotaline in rat. J Ethnopharmacol2007;111:567-572.28. Cai BX, Li XY, Chen JH, Tang YB, Wang GL, Zhou JG,Qui QY, Guan YY. Ginsenoside-Rd, a new voltage-independentCa2+ entry blocker, reverses basilar hypertrophicremodeling in stroke-prone renovascular hypertensiverats. Eur J Pharmacol 2009;606:142-149.29. Chen RJ, Chung TY, Li FY, Lin NH, Tzen JT. Effect ofsugar positions in ginsenosides and their inhibitory potencyon Na+/K+-ATPase activity. Acta Pharmacol Sin2009;30:61-69.30. Choi SH, Lee JH, Pyo MK, Lee BH, Shin TJ, HwangSH, Kim BR, Lee SM, Oh JW, Kim HC et al. MutationsLeu427, Asn428, and Leu431 residues within transmembranedomain-I-segment 6 attenuate ginsenoside-mediatedL-type Ca(2+) channel current inhibitions. Biol PharmBull 2009;32:1224-1230.31. Jeon BH, Kim CS, Park KS, Lee JW, Park JB, Kim KJ,Kim SH, Chang SJ, Nam KY. Effect of Korea red ginsengon the blood pressure in conscious hypertensive rats. GenPharmacol 2000;35:135-141.32. Kang SY, Schini-Kerth VB, Kim ND. Ginsenosides ofthe protopanaxatriol group cause endothelium-dependentrelaxation in the rat aorta. Life Sci 1995;56:1577-1586.33. Vuksan V, Stavro M, Woo M, Leiter LA, Sung MK,Sievenpiper JL. Korean red ginseng (Panax ginseng) canlower blood pressure in individuals with hypertension: arandomized controlled trial. Proceedings of the 9th InternationalGinseng Symposium; 2006 Sep 25-28; Geumsan,Korea. Seoul: Korean Society of Ginseng, 2006.34. Kim ND, Kang SY, Schini VB. Ginsenosides evoke endothelium-dependent vascular relaxation in rat aorta. GenPharmacol 1994;25:1071-1077.35. Baek EB, Yoo HY, Park SJ, Chung YS, Hong EK, KimSJ. Inhibition of arterial myogenic responses by a mixedaqueous extract of salvia miltiorrhiza and Panax notoginseng(PASEL) showing antihypertensive effects. Korean JPhysiol Pharmacol 2009;13:287-293.36. Wagner HN, Liu X. The international textbook of cardiology.New York: Pergamon Press, 1987.37. Liu L, Shi R, Shi Q, Cheng Y, Huo Y. Protective effect ofsaponins from Panax notoginseng against doxorubicininducedcardiotoxicity in mice. Planta Med 2008;74:203-209.38. Qin N, Gong QH, Wei LW, Wu Q, Huang XN. Total ginsenosidesinhibit the right ventricular hypertrophy inducedby monocrotaline in rats. Biol Pharm Bull 2008;31:1530-1535.39. Deng J, Wang YW, Chen WM, Wu Q, Huang XN. Roleof nitric oxide in ginsenoside Rg(1)-induced protectionagainst left ventricular hypertrophy produced by abdominalaorta coarctation in rats. Biol Pharm Bull 2010;33:631-635.40. Wang YG, Zima AV, Ji X, Pabbidi R, Blatter LA, LipsiusSL. Ginsenoside Re suppresses electromechanical alter23Kim et al. Pharmacological Eff ects of Ginseng on Cardiovascular Diseasehttp://ginsengres.orgnans in cat and human cardiomyocytes. Am J PhysiolHeart Circ Physiol 2008;295:H851-H859.41. Wang Z, Li M, Wu WK, Tan HM, Geng DF. GinsenosideRb1 preconditioning protects against myocardial infarctionafter regional ischemia and reperfusion by activationof phosphatidylinositol-3-kinase signal transduction. CardiovascDrugs Ther 2008;22:443-452.42. Deng J, Lv XT, Wu Q, Huang XN. Ginsenoside Rg(1)inhibits rat left ventricular hypertrophy induced by abdominalaorta coarctation: involvement of calcineurin andmitogen-activated protein kinase signalings. Eur J Pharmacol2009;608:42-47.43. Wang YL, Wang CY, Zhang BJ, Zhang ZZ. Shenfu injectionsuppresses apoptosis by regulation of Bcl-2 andcaspase-3 during hypoxia/reoxygenation in neonatal ratcardiomyocytes in vitro. Mol Biol Rep 2009;36:365-370.44. Yook T, Yu J, Lee H, Song B, Kim L, Roh J, Shin J, LimS. Comparing the effects of distilled rehmannia glutinosa,wild ginseng and astragali radix pharmacopuncture withheart rate variability (HRV): a randomized, sham-controlledand double-blind clinical trial. J Acupunct MeridianStud 2009;2:239-247.45. Zhu D, Wu L, Li CR, Wang XW, Ma YJ, Zhong ZY, ZhaoHB, Cui J, Xun SF, Huang XL et al. Ginsenoside Rg1protects rat cardiomyocyte from hypoxia/reoxygenationoxidative injury via antioxidant and intracellular calciumhomeostasis. J Cell Biochem 2009;108:117-124.46. Kim TH, Lee SM. The effects of ginseng total saponin,panaxadiol and panaxatriol on ischemia/reperfusion injuryin isolated rat heart. Food Chem Toxicol 2010;48:1516-1520.47. Wu Y, Xia ZY, Dou J, Zhang L, Xu JJ, Zhao B, Lei S, LiuHM. Protective effect of ginsenoside Rb1 against myocardialischemia/reperfusion injury in streptozotocin-induceddiabetic rats. Mol Biol Rep 2011;38:4327-4335.48. Bodiga S, Wang W, Oudit GY. Use of ginseng to reducepost-myocardial adverse myocardial remodeling: applyingscientific principles to the use of herbal therapies. JMol Med (Berl) 2011;89:317-320.49. Guo J, Gan XT, Haist JV, Rajapurohitam V, Zeidan A,Faruq NS, Karmazyn M. Ginseng inhibits cardiomyocytehypertrophy and heart failure via NHE-1 inhibitionand attenuation of calcineurin activation. Circ Heart Fail2011;4:79-88.50. Tsutsumi YM, Tsutsumi R, Mawatari K, Nakaya Y,Kinoshita M, Tanaka K, Oshita S. Compound K, a metaboliteof ginsenosides, induces cardiac protection mediatednitric oxide via Akt/PI3K pathway. Life Sci 2011;88:725-729.51. Zhou H, Hou SZ, Luo P, Zeng B, Wang JR, Wong YF,Jiang ZH, Liu L. Ginseng protects rodent hearts fromacute myocardial ischemia-reperfusion injury throughGR/ER-activated RISK pathway in an endothelial NOSdependentmechanism. J Ethnopharmacol 2011;135:287-298.52. Criqui MH, Langer RD, Fronek A, Feigelson HS, KlauberMR, McCann TJ, Browner D. Mortality over a periodof 10 years in patients with peripheral arterial disease. NEngl J Med 1992;326:381-386.53. Schouten O, Poldermans D. Cardiac risk in non-cardiacsurgery. Br J Surg 2007;94:1185-1186.54. He F, Guo R, Wu SL, Sun M, Li M. Protective effectsof ginsenoside Rb1 on human umbilical vein endothelialcells in vitro. J Cardiovasc Pharmacol 2007;50:314-320.55. Kim YM, Namkoong S, Yun YG, Hong HD, Lee YC,Ha KS, Lee H, Kwon HJ, Kwon YG, Kim YM. Waterextract of Korean red ginseng stimulates angiogenesis byactivating the PI3K/Akt-dependent ERK1/2 and eNOSpathways in human umbilical vein endothelial cells. BiolPharm Bull 2007;30:1674-1679.56. Leung KW, Yung KK, Mak NK, Yue PY, Luo HB, ChengYK, Fan TP, Yeung HW, Ng TB, Wong RN. Angiomodulatoryand neurological effects of ginsenosides. Curr MedChem 2007;14:1371-1380.57. Nakaya Y, Mawatari K, Takahashi A, Harada N, Hata A,Yasui S. The phytoestrogen ginsensoside Re activates potassiumchannels of vascular smooth muscle cells throughPI3K/Akt and nitric oxide pathways. J Med Invest2007;54:381-384.58. Leung KW, Leung FP, Huang Y, Mak NK, Wong RN.Non-genomic effects of ginsenoside-Re in endothelialcells via glucocorticoid receptor. FEBS Lett 2007;581:2423-2428.59. Papapetropoulos A. A ginseng-derived oestrogen receptorbeta (ERbeta) agonist, Rb1 ginsenoside, attenuates capillarymorphogenesis. Br J Pharmacol 2007;152:172-174.60. Yu J, Eto M, Akishita M, Kaneko A, Ouchi Y, Okabe T.Signaling pathway of nitric oxide production inducedby ginsenoside Rb1 in human aortic endothelial cells: apossible involvement of androgen receptor. Biochem BiophysRes Commun 2007;353:764-769.61. Yu LC, Chen SC, Chang WC, Huang YC, Lin KM, LaiPH, Sung HW. Stability of angiogenic agents, ginsenosideRg1 and Re, isolated from Panax ginseng: in vitro and invivo studies. Int J Pharm 2007;328:168-176.62. Lei Y, Gao Q, Chen KJ. Effects of extracts from Panaxnotoginseng and Panax ginseng fruit on vascular endothelialcell proliferation and migration in vitro. Chin J IntegrMed 2008;14:37-41.63. Lin KM, Hsu CH, Rajasekaran S. Angiogenic evaluation 24J. Ginseng Res. Vol. 36, No. 1, 16-26 (2012)of ginsenoside Rg1 from Panax ginseng in fluorescenttransgenic mice. Vascul Pharmacol 2008;49:37-43.64. Chan LS, Yue PY, Mak NK, Wong RN. Role of microRNA-214 in ginsenoside-Rg1-induced angiogenesis. Eur JPharm Sci 2009;38:370-377.65. Hong SJ, Wan JB, Zhang Y, Hu G, Lin HC, Seto SW,Kwan YW, Lin ZX, Wang YT, Lee SM. Angiogenic effectof saponin extract from Panax notoginseng on HUVECsin vitro and zebrafi sh in vivo. Phytother Res 2009;23:677-686.66. Wan JB, Lee SM, Wang JD, Wang N, He CW, Wang YT,Kang JX. Panax notoginseng reduces atherosclerotic lesionsin ApoE-deficient mice and inhibits TNF-alphainducedendothelial adhesion molecule expression andmonocyte adhesion. J Agric Food Chem 2009;57:6692-6697.67. Hien TT, Kim ND, Pokharel YR, Oh SJ, Lee MY, KangKW. Ginsenoside Rg3 increases nitric oxide productionvia increases in phosphorylation and expression of endothelialnitric oxide synthase: essential roles of estrogenreceptor-dependent PI3-kinase and AMP-activated proteinkinase. Toxicol Appl Pharmacol 2010;246:171-183.68. Jeong A, Lee HJ, Jeong SJ, Lee HJ, Lee EO, Bae H, KimSH. Compound K inhibits basic fi broblast growth factorinducedangiogenesis via regulation of p38 mitogen activatedprotein kinase and AKT in human umbilical veinendothelial cells. Biol Pharm Bull 2010;33:945-950.69. Cheung LW, Leung KW, Wong CK, Wong RN, Wong AS.Ginsenoside-Rg1 induces angiogenesis via non-genomiccrosstalk of glucocorticoid receptor and fi broblast growthfactor receptor-1. Cardiovasc Res 2011;89:419-425.70. He W, Wu WK, Wu YL, Yang XH, Lin QX, Yu WH.Ginsenoside-Rg1 mediates microenvironment-dependentendothelial differentiation of human mesenchymal stemcells in vitro. J Asian Nat Prod Res 2011;13:1-11.71. Xu Z, Lan T, Wu W, Wu Y. The effects of ginsenoside Rb1on endothelial damage and ghrelin expression induced byhyperhomocysteine. J Vasc Surg 2011;53:156-164.72. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxingand contracting factors. FASEB J 1989;3:2007-2018.73. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from arteryand vein. Circ Res 1989;65:1-21.74. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology,pathophysiology, and pharmacology. Pharmacol Rev1991;43:109-142.75. Leung KW, Cheng YK, Mak NK, Chan KK, Fan TP,Wong RN. Signaling pathway of ginsenoside-Rg1 leadingto nitric oxide production in endothelial cells. FEBS Lett2006;580:3211-3216.76. Kang YJ, Sohn JT, Chang KC. Relaxation of caninecorporal smooth muscle relaxation by ginsenoside saponinRg3 is independent from eNOS activation. Life Sci2005;77:74-84.77. Jovanovski E, Jenkins A, Dias AG, Peeva V, SievenpiperJ, Arnason JT, Rahelic D, Josse RG, Vuksan V. Effects ofKorean red ginseng (Panax ginseng C.A. Mayer) and itsisolated ginsenosides and polysaccharides on arterial stiffnessin healthy individuals. Am J Hypertens 2010;23:469-472.78. Lee JY, Lim KM, Kim SY, Bae ON, Noh JY, Chung SM,Kim K, Shin YS, Lee MY, Chung JH. Vascular smoothmuscle dysfunction and remodeling induced by ginsenosideRg3, a bioactive component of ginseng. Toxicol Sci2010;117:505-514.79. Wang T, Yu XF, Qu SC, Xu HL, Sui DY. GinsenosideRb3 inhibits angiotensin II-induced vascular smoothmuscle cells proliferation. Basic Clin Pharmacol Toxicol2010;107:685-689.80. Wu L, Zhang W, Tang YH, Li H, Chen BY, Zhang GM,Deng CQ. Effect of total saponins of “Panax notoginsengroot” on aortic intimal hyperplasia and the expressions ofcell cycle protein and extracellular matrix in rats. Phytomedicine2010;17:233-240.81. Rhee MY, Kim YS, Bae JH, Nah DY, Kim YK, Lee MM,Kim HY. Effect of Korean red ginseng on arterial stiffnessin subjects with hypertension. J Altern Complement Med2011;17:45-49.82. Tamura Y. Effects of Korean red ginseng on eicosanoidbiosynthesis in platelets and vascular smooth musclecells. Proceedings of the 6th Internationa1 Ginseng Symposium;1993 Sep 6-9; Seoul, Korea. Daejeon: KoreaGinseng & Tobacco Research Institute, 1993.83. Harima S, Matsuda H, Kubo M. Study of various rhubarbsregarding the cathartic effect and endotoxin-induceddisseminated intravascular coagulation. Biol Pharm Bull1994;17:1522-1525.84. Jin YR, Yu JY, Lee JJ, You SH, Chung JH, Noh JY, ImJH, Han XH, Kim TJ, Shin KS et al. Antithrombotic andantiplatelet activities of Korean red ginseng extract. BasicClin Pharmacol Toxicol 2007;100:170-175.85. Lee WM, Kim SD, Park MH, Cho JY, Park HJ, Seo GS,Rhee MH. Inhibitory mechanisms of dihydroginsenosideRg3 in platelet aggregation: critical roles of ERK2 andcAMP. J Pharm Pharmacol 2008;60:1531-1536.86. Li GX, Liu ZQ. The protective effects of ginsenosides onhuman erythrocytes against hemin-induced hemolysis.Food Chem Toxicol 2008;46:886-892.87. Wang J, Huang ZG, Cao H, Wang YT, Hui P, Hoo C, LiSP. Screening of anti-platelet aggregation agents from25Kim et al. Pharmacological Eff ects of Ginseng on Cardiovascular Diseasehttp://ginsengres.orgPanax notoginseng using human platelet extraction andHPLC-DAD-ESI-MS/MS. J Sep Sci 2008;31:1173-1180.88. Yang JY, Sun K, Wang CS, Guo J, Xue X, Liu YY, ZhengJ, Fan JY, Liao FL, Han JY. Improving effect of posttreatmentwith Panax notoginseng saponins on lipopolysaccharide-induced microcirculatory disturbance in ratmesentery. Clin Hemorheol Microcirc 2008;40:119-131.89. Lau AJ, Toh DF, Chua TK, Pang YK, Woo SO, Koh HL.Antiplatelet and anticoagulant effects of Panax notoginseng:comparison of raw and steamed Panax notoginsengwith Panax ginseng and Panax quinquefolium. J Ethnopharmacol2009;125:380-386.90. Lee JG, Lee YY, Kim SY, Pyo JS, Yun-Choi HS, Park JH.Platelet antiaggregating activity of ginsenosides isolatedfrom processed ginseng. Pharmazie 2009;64:602-604.91. Lee JG, Lee YY, Wu B, Kim SY, Lee YJ, Yun-Choi HS,Park JH. Inhibitory activity of ginsenosides isolated fromprocessed ginseng on platelet aggregation. Pharmazie2010;65:520-522.92. Lee YH, Lee BK, Choi YJ, Yoon IK, Chang BC, GwakHS. Interaction between warfarin and Korean red ginsengin patients with cardiac valve replacement. Int J Cardiol2010;145:275-276.93. Yi XQ, Li T, Wang JR, Wong VK, Luo P, Wong IY, JiangZH, Liu L, Zhou H. Total ginsenosides increase coronaryperfusion fl ow in isolated rat hearts through activation ofPI3K/Akt-eNOS signaling. Phytomedicine 2010;17:1006-1015.94. Ahn CM, Hong SJ, Choi SC, Park JH, Kim JS, Lim DS.Red ginseng extract improves coronary fl ow reserve andincreases absolute numbers of various circulating angiogeniccells in patients with first ST-segment elevationacute myocardial infarction. Phytother Res 2011;25:239-249.95. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolicsyndrome among US adults: findings from thethird National Health and Nutrition Examination Survey.JAMA 2002;287:356-359.96. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA,Oliver BB, Su JL, Sundseth SS, Winegar DA, BlanchardDE, Spencer TA et al. Activation of the nuclear receptorLXR by oxysterols defi nes a new hormone response pathway.J Biol Chem 1997;272:3137-3140.97. Karu N, Reifen R, Kerem Z. Weight gain reduction inmice fed Panax ginseng saponin, a pancreatic lipase inhibitor.J Agric Food Chem 2007;55:2824-2828.98. Trinh HT, Han SJ, Kim SW, Lee YC, Kim DH. Bifi dusfermentation increases hypolipidemic and hypoglycemiceffects of red ginseng. J Microbiol Biotechnol2007;17:1127-1133.99. Hwang SY, Son DJ, Kim IW, Kim DM, Sohn SH, Lee JJ,Kim SK. Korean red ginseng attenuates hypercholesterolemia-enhanced platelet aggregation through suppressionof diacylglycerol liberation in high-cholesterol-diet-fedrabbits. Phytother Res 2008;22:778-783.100. Zhang YG, Zhang HG, Zhang GY, Fan JS, Li XH, LiuYH, Li SH, Lian XM, Tang Z. Panax notoginseng saponinsattenuate atherosclerosis in rats by regulating theblood lipid profi le and an anti-infl ammatory action. ClinExp Pharmacol Physiol 2008;35:1238-1244.101. Liu G, Wang B, Zhang J, Jiang H, Liu F. Total panax notoginsenosidesprevent atherosclerosis in apolipoproteinE-knockout mice: role of downregulation of CD40 andMMP-9 expression. J Ethnopharmacol 2009;126:350-354.102. Jia Y, Li ZY, Zhang HG, Li HB, Liu Y, Li XH. Panaxnotoginseng saponins decrease cholesterol ester via upregulatingATP-binding cassette transporter A1 in foamcells. J Ethnopharmacol 2010;132:297-302.103. Kwak YS, Kyung JS, Kim JS, Cho JY, Rhee MH.Anti-hyperlipidemic effects of red ginseng acidic polysaccharidefrom Korean red ginseng. Biol Pharm Bull2010;33:468-472.104. Liu Y, Zhang HG, Jia Y, Li XH. Panax notoginseng saponinsattenuate atherogenesis accelerated by zymosan inrabbits. Biol Pharm Bull 2010;33:1324-1330.105. Xia W, Sun C, Zhao Y, Wu L. Hypolipidemic and antioxidantactivities of sanchi (radix notoginseng) in rats fedwith a high fat diet. Phytomedicine 2011;18:516-520.106. Li J, Xie ZZ, Tang YB, Zhou JG, Guan YY. Ginsenoside-Rd, a purifi ed component from Panax notoginsengsaponins, prevents atherosclerosis in apoE knockout mice.Eur J Pharmacol 2011;652:104-110.107. Bolli R. Superoxide dismutase 10 years later: a drug insearch of a use. J Am Coll Cardiol 1991;18:231-233.108. Gross GJ, Farber NE, Hardman HF, Warltier DC. Beneficialactions of superoxide dismutase and catalase instunned myocardium of dogs. Am J Physiol 1986;250(3Pt 2):H372- H377.109. Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurementof free radical generation following reperfusionof ischemic myocardium. Proc Natl Acad Sci U S A1987;84:1404-1407.110. Xie YW, Shen W, Zhao G, Xu X, Wolin MS, Hintze TH.Role of endothelium-derived nitric oxide in the modulationof canine myocardial mitochondrial respiration invitro. Implications for the development of heart failure.Circ Res 1996;79:381-387.111. Taniguchi M, Wilson C, Hunter CA, Pehowich DJ, ClanachanAS, Lopaschuk GD. Dichloroacetate improves 26J. Ginseng Res. Vol. 36, No. 1, 16-26 (2012)cardiac effi ciency after ischemia independent of changesin mitochondrial proton leak. Am J Physiol Heart CircPhysiol 2001;280:H1762- H1769.112. Abdel-Wahhab MA, Ahmed HH. Protective effect ofKorean Panax ginseng against chromium VI toxicity andfree radicals generation in rats. J Ginseng Res 2004;28:11-17.113. Chung YH, Kim KW, Oura H. Effects of ginsenosideRb2 on the anti-oxidants in senescence-accelerated mice(SAM-R/1). Proceedings of the 6th Internationa1 GinsengSymposium; 1993 Sep 6-9; Seoul, Korea. Daejeon: KoreaGinseng & Tobacco Research Institute, 1993.114. Chang HM; Chinese University of Hong Kong; ChineseMedicinal Research Centre. Advances in Chinese medicinalmaterials research. Philadelphia: World Scientifi c,1985.115. Kim H, Chen X, Gillis CN. Ginsenosides protect pulmonaryvascular endothelium against free radical-inducedinjury. Biochem Biophys Res Commun 1992;189:670-676.116. Kim YK, Guo Q, Packer L. Free radical scavengingactivity of red ginseng aqueous extracts. Toxicology2002;172:149-156.117. Samukawa K, Suzuki Y, Ohkubo N, Aoto M, SakanakaM, Mitsuda N. Protective effect of ginsenosides Rg(2)and Rh(1) on oxidation-induced impairment of erythrocytemembrane properties. Biorheology 2008;45:689-700.118. Li XT, Chen R, Jin LM, Chen HY. Regulation on energymetabolism and protection on mitochondria of Panaxginseng polysaccharide. Am J Chin Med 2009;37:1139-1152.119. Li J, Ichikawa T, Jin Y, Hofseth LJ, Nagarkatti P, NagarkattiM, Windust A, Cui T. An essential role of Nrf2 inAmerican ginseng-mediated anti-oxidative actions in cardiomyocytes.J Ethnopharmacol 2010;130:222-230.120. Fu Y, Ji LL. Chronic ginseng consumption attenuatesage-associated oxidative stress in rats. J Nutr2003;133:3603-3609.121. Chen X. Cardiovascular protection by ginsenosides andtheir nitric oxide releasing action. Clin Exp PharmacolPhysiol 1996;23:728-732.122. Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C.Ginsenoside Rb1 blocks homocysteine-induced endothelialdysfunction in porcine coronary arteries. J Vasc Surg2005;41:861-868.123. Wang X, Chai H, Yao Q, Chen C. Molecular mechanismsof HIV protease inhibitor-induced endothelial dysfunction.J Acquir Immune Defi c Syndr 2007;44:493-499.124. Xie JT, Shao ZH, Vanden Hoek TL, Chang WT, Li J,Mehendale S, Wang CZ, Hsu CW, Becker LB, Yin JJ etal. Antioxidant effects of ginsenoside Re in cardiomyocytes.Eur J Pharmacol 2006;532:201-207.125. Deng HL, Zhang JT. Anti-lipid peroxilative effect of ginsenosideRb1 and Rg1. Chin Med J (Engl) 1991;104:395-398.126. Lim JH, Wen TC, Matsuda S, Tanaka J, Maeda N, PengH, Aburaya J, Ishihara K, Sakanaka M. Protection of ischemichippocampal neurons by ginsenoside Rb1, a mainingredient of ginseng root. Neurosci Res 1997;28:191-200.127. Tian J, Fu F, Geng M, Jiang Y, Yang J, Jiang W, Wang C,Liu K. Neuroprotective effect of 20(S)-ginsenoside Rg3on cerebral ischemia in rats. Neurosci Lett 2005;374:92-97.128. Lu JM, Yao Q, Chen C. Ginseng compounds: an updateon their molecular mechanisms and medical applications.Curr Vasc Pharmacol 2009;7:293-302.

External research may be publically accessed through academic databases:

Pubmed, Medlink, Academic Search Premier, US National Library of Medicine National Institutes of Health, etc.


The following investigations had drug development and possible clinical use of Panax ginseng in mind. Elipulse(R) is a natural health product supplement that does not aim to treat or cure diseases, but rather utilize the limited, beneficial effects of Panax ginsenosides to benefit its users in a meaningful, productive way. 


These statements has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. However, these very recent findings may explain the pharmacological mechanisms behind Panax ginseng. This collection of findings do not represent all findings currently available at this time but only a small portion.

References (nonformatted)


129. Mingfei Zeng, Linmei Pan, Shunmei Qi, Yuntai Cao, Huaxu Zhu, Liwei Guo, Jing Zhou, Systematic review of recent advances in pharmacokinetics of four classical Chinese medicines used for the treatment of cerebrovascular disease, Fitoterapia, Volume 88, July 2013, Pages 50-75, ISSN 0367-326X, ( Keywords: ADME (absorption, distribution, metabolism and excretion); Cerebrovascular disease; Chinese medicine; Pharmacokinetics; Bioavailability; Drug interaction


130. Zheng M, Qu L, Lou Y. Effects of icariin combined with Panaxnotoginseng saponins on ischemia reperfusion-induced cognitive impairments related with oxidative stress and CA1 of hippocampalneurons in rat. Phytother Res 2008;22:597–604.


131. Chuang CM, Hsieh CL, Lin HY. Panax notoginseng Burk attenuates impairment of learning and memory functions and increases ED1,BDNF and beta-secretase immunoreactive cells in chronic stageischemia–reperfusion injured rats. Am J Chin Med 2008;36:685–93.


132. Li H, Deng CQ, Chen BY, Zhang SP, Liang Y, Luo XG. Total saponins of Panax notoginseng modulate the expression of caspases and attenuateapoptosis in rats following focal cerebral ischemia–reperfusion.J Ethnopharmacol 2009;121:412–8.


133.  Son HY, Han HS, Jung HW, Park YK. Panax notoginseng attenuates the infarct volume in rat ischemic brain and the inflammatory response ofmicroglia. J Pharmacol Sci 2009;109:368–79.


134. Lau AJ, Toh DF, Chua TK, Pang YK, Woo SO, Koh HL. Antiplatelet and anticoagulant effects of Panax notoginseng: comparison of raw and steamed Panax notoginseng with Panax ginseng and Panax quinquefolium. J Ethnopharmacol. 2009 Sep 25;125(3):380-6. doi: 10.1016/j.jep.2009.07.038. Epub 2009 Aug 7. PubMed PMID: 19665534.


135. Zheng M., Qu L., Lou. Effects of icariin combined with Panax notoginseng saponins on ischemia reperfusion-induced cognitive impairments related with oxidative stress and CA1 of hippocampal neurons in rat . Phytotherapy Research. (2008). 22 (5) , pp. 597-604.


136. Kim SY, Seo SK, Choi YM, Jeon YE, Lim KJ, Cho S, Choi YS, Lee BS. Effects of red ginseng supplementation on menopausal symptoms and cardiovascular risk factors in postmenopausal women: a double-blind randomized controlled trial. Menopause. 2012 Apr;19(4):461-6. doi: 10.1097/gme.0b013e3182325e4b. PubMed PMID: 22027944.


137. Rhee MY, Kim YS, Bae JH, Nah DY, Kim YK, Lee MM, Kim HY. Effect of Korean red ginseng on arterial stiffness in subjects with hypertension. J Altern Complement Med. 2011 Jan;17(1):45-9. doi: 10.1089/acm.2010.0065. Epub 2011 Jan 16. PubMed PMID: 21235416.


138. "Coronary artery bypass graft - Alternatives ." Coronary artery bypass graft. National Health Service UK, n.d. Web. 29 Apr. 2014. <>.